Författare: johan@emergers.se

BONZUN: Evolve to drive doubling of revenues in 2023

Analys, Research

After a comprehensive adjustment of business focus, balance sheet, costs and valuation in 2022, along with a recent restocking of the...

Read More

CAPSEK: Ökade investeringar och flertal nyheter i pipeline för CapSek i vår

Interview, Okategoriserade

Efter stora förändringar av både värdena på portföljinnehaven såväl som själva portföljen lägger Northern CapSek Ventures AB ett...

Read More

SIMRIS ALG: Transforming to build an integrated multi-vertical microalgae and cyanobacteria company  

Analys, Research

Simris’ expanded objective to leverage the acquisition of Cyano Biotech in Q3’22, enter the high-value biopharma space and build a...

Read More

CAPSEK | Klash Studio satsar på spelstudios för att nå 80 000 kunder globalt om fem år

Okategoriserade

Göteborgsbaserade investmentbolaget Northern CapSek Ventures AB (”CapSek”) portföljbolag Klash Studio erbjuder en molntjänst som...

Read More

NANEXA: Validation from Novo Nordisk positions Nanexa for an eventful year ahead

Analys, Research

After a news packed Q4 2022, including an exclusivity and evaluation agreement with Novo Nordisk, start of Phase I with NEX-20 and two...

Read More

CRUNCHFISH: Video interview with CEO Joachim Samuelsson on ”the paradigm shift in payments” + feedback from India: ”Scale it up”

Analys, Research

https://youtu.be/kmv2PDFQQdM Read the press release from Crunchfish here READ EMERGERS’ EQUITY RESEARCH ON CRUNCHFISH HERE CRUNCHFISH:...

Read More

QLUCORE: Interview with CEO Carl-Johan Ivarsson about the important issues in 2023 and the revenue target of SEK 300 million in 2027

Analys, Research

READ EMERGERS’ EQUITY RESEARCH ON QLUCORE HERE QLUCORE: At the vanguard of both oncology research and life science M&A With a strong...

Read More

BONZUN: Evidence-based DTx scaling up to combat stress and infertility

Analys, Research

We re-initiate coverage on digital therapeutics (DTx) company Bonzun that offers evidence-based patient support for fertility treatments...

Read More

QLUCORE: At the vanguard of both oncology research and life science M&A

Analys, Research

With a strong trend in oncology and life science R&D in favour of precision medicine, data analysis and AI, Qlucore is uniquely...

Read More

NANEXA: Novo Nordisk deal offers both scientific validation and investor-friendly financing

Analys, Research

The combination of an exclusive evaluation agreement and directed share issue to Novo Nordisk, global leader in diabetes treatment,...

Read More

For new research on growth stocks, sign up to our newsletter